ArticleClinical ophthalmology (Auckland, N.Z.)2026
Axial Length Control Using Repeated Low-Level Red Light Combined with Orthokeratology Compared with Orthokeratology Alone in Rapidly Progressing Myopic Children.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy and safety of combining repeated low-level red light (RLRL) therapy with orthokeratology (OK) in slowing axial elongation in children with rapid myopia progression. Patients and Methods: This retrospective cohort included 72 children aged 8-14 years (RLRL+OK, n=36; OK-only, n=36) meeting the rapid-progressor definition (>0.40 mm/year axial elongation. One eye per child was randomly selected. Axial length (AL) was measured at baseline and at 3, 6, and 12 months. Inverse probability of treatment weighting (IPTW) based on age, sex, and baseline AL achieved good balance between groups. The primary outcome was the 12-month AL change, assessed using IPTW-weighted linear mixed-effects models adjusted for covariates. Prespecified subgroup analyses were stratified by age (<10 vs ≥10 years). Sensitivity analyses included propensity score matching (PSM), per-protocol analysis (PP; adherence ≥80%), and dose-response evaluation. Safety was assessed using slit-lamp biomicroscopy and macular OCT imaging. Results: At 12 months, the RLRL+OK group had significantly less elongation than OK-only (mean difference -0.298 mm; 95% CI -0.388 to -0.209; p<0.001), with significant group×time interactions from 3 months. Benefits were consistent across age subgroups without effect modification. Sensitivity analyses confirmed robustness: PSM (-0.255 mm; p<0.001) and PP (-0.298 mm; p<0.001). Dose-response showed each 10% higher adherence reduced elongation by -0.148 mm (p<0.001). No clinically significant adverse events were detected. Conclusion: RLRL combined with OK significantly reduced axial elongation in rapid-progressing children compared with OK alone, with a clear adherence-dependent effect and reassuring short-term safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.